Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ: SUPN · IEX Real-Time Price · USD
27.27
0.29 (1.07%)
May 25, 2022 4:00 PM EDT - Market closed
Market Cap1.46B
Revenue (ttm)601.35M
Net Income (ttm)73.35M
Shares Out53.41M
EPS (ttm)1.31
PE Ratio20.75
Forward PE20.16
Dividendn/a
Ex-Dividend Daten/a
Volume298,779
Open26.89
Previous Close26.98
Day's Range26.36 - 27.36
52-Week Range23.15 - 34.50
Beta1.13
AnalystsBuy
Price Target36.21 (+32.8%)
Earnings DateMay 9, 2022

About SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The ...

IndustryPharmaceuticals
IPO DateMay 1, 2012
CEOJack Khattar
Employees575
Stock ExchangeNASDAQ
Ticker SymbolSUPN
Full Company Profile

Financial Performance

In 2021, SUPN's revenue was $579.78 million, an increase of 11.41% compared to the previous year's $520.40 million. Earnings were $53.42 million, a decrease of -57.92%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SUPN stock is "Buy." The 12-month stock price forecast is 36.21, which is an increase of 32.78% from the latest price.

Price Target
$36.21
(32.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Supernus Announces First Quarter 2022 Financial Results

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...

2 weeks ago - GlobeNewsWire

Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022

ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centra...

3 weeks ago - GlobeNewsWire

FDA Approves Expanded Use Of Supernus' Viloxazine In Adult ADHD Patients

The FDA approved an expanded indication for Supernus Pharmaceuticals Inc's (NASDAQ: SUPN) Qelbree (viloxazine extended-release capsules) for attention deficit hyperactivity disorder (ADHD) in adult pati...

3 weeks ago - Benzinga

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md. , May 2, 2022 /PRNewswire/ -- Supernus Pharmaceuticals, Inc. (Nas...

3 weeks ago - PRNewsWire

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

1 month ago - GlobeNewsWire

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

1 month ago - GlobeNewsWire

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

2 months ago - GlobeNewsWire

Supernus to Participate in Annual Cowen Health Care Conference

ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent...

2 months ago - GlobeNewsWire

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

2 months ago - GlobeNewsWire

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Febru...

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

3 months ago - GlobeNewsWire

Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?

Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

3 months ago - Zacks Investment Research

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Why the Earnings Surprise Streak Could Continue for Supernus (SUPN)

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 months ago - Zacks Investment Research

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

5 months ago - GlobeNewsWire

Supernus Pharmaceuticals Targeted in Ransomware Incident

The attack had no significant impact on the business and did not cause any significant disruption to Company's operations

6 months ago - GlobeNewsWire

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow Acquisition strengthens Parkinson's disease portfolio and diversifies revenue and cash flow

6 months ago - GlobeNewsWire

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender O...

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of...

6 months ago - GlobeNewsWire

Supernus to Participate in Upcoming November Investor Conferences

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

6 months ago - GlobeNewsWire

Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Beat Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 90.48% and 5.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Supernus Pharmaceuticals: Q3 Earnings Insights

Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Supernus Announces Third Quarter 2021 Financial Results

ROCKVILLE, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

6 months ago - GlobeNewsWire

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of centr...

6 months ago - GlobeNewsWire

Why Supernus' Acquisition of Adamas Is a Smart Move

Adamas looks like a good fit for Supernus.

7 months ago - The Motley Fool

SHAREHOLDER ALERT: WeissLaw LLP Investigates Adamas Pharmaceuticals, Inc.

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Adamas Pharmaceuticals, Inc. ("Adamas" ...

7 months ago - PRNewsWire

Supernus Pharmaceuticals to acquire this Pharmaceuticals company for $400 million

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals (NASDAQ: ADMS). Supernus is to purchase this company a tender o...

7 months ago - Invezz